New Rescue Helicopters A Boost For Northern Rescue Helicopters
Northern Rescue Helicopter Limited CEO Ian MacPherson has thanked the Government for helping fund the purchase of more modern rescue helicopters.
The first of three late model helicopters (AW169s) will enter service in Ardmore, before transitioning to Whangārei later this year.
MacPherson says the rollout is being planned to ensure service continuity while enabling a smooth integration of the new aircraft into Northern Rescue's Northland and Auckland rescue helicopter operations.
'The new models are replacing aircraft between fifteen and thirty years old, so this is a significant and carefully planned upgrade project that will improve efficiency and reduce maintenance costs,' says MacPherson.
'This is about the greater good of our communities and ensuring everyone has access to the best air ambulance technology and capability day and night. These new aircraft will ensure we are running an increasingly sustainable service with the best aeromedical technology available.'
MacPherson says in essence, the new aircraft boosts Northern Rescue's ability to deliver high levels of clinical care and promote equity of access across Northland, particularly in remote regions.
'Additionally, the AW169 offers the opportunity to optimise the rear cabin as a sophisticated clinical environment that supports this model of care.
'That's because our new helicopters have a larger rear cabin for our clinicians to work in. They have 360-degree access to patients. Our highly trained medical teams can be examining and treating patients from the moment they enter the aircraft which increases the likelihood of a full recovery.
'Support from the Health NZ-Te Whatu Ora's /ACC Ambulance Team, the Government has made it possible for us to advance our aeromedical care across Auckland and Northland as we roll out these newer helicopters across our regions,' adds MacPherson.
In fact, the Government is supporting the replacement of nine rescue helicopters with newer aircraft around the country, by investing a total of $14.7 million ($8.2 million by Health New Zealand | Te Whatu Ora and $6.5 million by ACC) in the year to July 2025 – providing critical upgrades to ageing fleets.
MacPherson believes the arrival of newer helicopters represents a significant milestone for Northern Rescue.
'These new aircraft are essential to our operation as we continue to modernise our fleet and enhance aeromedical capability across the Northern Region. This upgrade is not only about embracing advanced technology, it also about acknowledging the unwavering community support that has shaped this service over decades.'
Adding to the need for new helicopters is the increasing demand for emergency air ambulance and rescue services.
'To meet this growing need, we are investing in aircraft that are safer, more reliable, and built for the complex demands of modern patient care. The AW169 enables our teams to respond rapidly and confidently across both urban and remote environments throughout Aotearoa New Zealand,' says MacPherson.
Northern Rescue Board Chair Paul Ahlers says that their team has done a great job working towards standardising the fleet.
'Transitioning to a single aircraft type streamlines training, maintenance, and operational procedures for our engineers, medical teams and pilots,' says Ahlers.
'This standardisation enhances safety, reduces downtime, and increases efficiency, allowing us to maximise the time we spend delivering our service to the benefit of our Northland, Auckland and Coromandel communities – we have many sponsors within these communities that offer us so much support throughout the year and allow our crews to deliver the high level of care the community deserves.
'This is a significant milestone in the ongoing development of our operation as we continue to utilise smarter and safer technology.'
Northern Rescue Chief Operating Officer and Critical Care Paramedic Karl Taylor says compared to the operation's legacy BK117 and S76 helicopters, the AW169 introduces next-generation capabilities.
'That includes state-of-the-art avionics, improved poor weather performance, advanced weather and terrain awareness and more powerful engines. It represents a significant leap forward in safety, performance, and operational resilience,' says Taylor.
'The rear cabin has been specifically designed to support high-level clinical care, featuring increased space, enhanced lighting, improved access to equipment and that full 360-degree access to patients.'
Taylor says the new aircraft also increases the search and rescue capability over sea and land, which means our adventure hungry communities will be even safer than ever because of these new aircraft.
'The rear cabin is also fully reconfigurable, enabling helicopter winch operations and the transport of critically ill patients between hospitals by specialised hospital teams. Our crews are certainly looking forward to working on our new AW169s,' says Taylor.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
6 hours ago
- Scoop
Northern Rescue And New Zealand Blood Service Use Battlefield Insights To Take Partnership To New Heights
Press Release – New Zealand Blood Service Northern Rescue Helicopter Limited, the operator of the Auckland Westpac Rescue Helicopter, and New Zealand Blood Service (NZBS) have launched a groundbreaking new trial, aiming to advance pre-hospital trauma care for some of Auckland, Northland and the Coromandel's most critically injured patients. The Study of Whole Blood in Frontline Trauma (SWiFT) Aotearoa trial builds on similar international trials in the United Kingdom and Canada. NZBS Transfusion Medicine Specialist Richard Charlewood says the New Zealand SWiFT trial, like those in the UK and Canada, will follow the learnings of military combat medicine, where the use of platelet rich whole blood transfusions has improved health outcomes for soldiers with severe trauma and blood loss. 'We often look to the military for lessons in emergency care. The unpredictable conditions they work in can push boundaries and lead to breakthroughs that have the ability to transform how civilian medical professionals respond in situations where every second counts.' The SWiFT Aotearoa trial will determine whether the inclusion of platelets in pre-hospital transfusion allows for earlier control of bleeding, potentially reducing the number of transfusions needed after arrival at the hospital and improving the probability of survival and recovery for patients. The randomised controlled trial will investigate the feasibility of making and delivering platelet-rich O-negative whole blood compared to the current O-negative whole blood carried by Northern Rescue for pre-hospital transfusion. Whole blood, like most blood components in New Zealand, has white cells removed, because they are not wanted and can cause reactions, but this process also removes the platelets. The platelet-rich whole blood is made using a new, more sophisticated filter that is able to remove the white cells while leaving most of the platelets. This trial aims to collect data on if platelet-rich whole blood might the be more effective for patients with life-threatening bleeding due to trauma. Platelets aid with blood clotting to stop bleeding and studies suggest that the earlier bleeding is brought under control, the better it is for the patient. Northern Rescue Deputy Medical Director Alana Harper describes the SWiFT Aotearoa trial as 'the next disruptive innovation in pre-hospital advanced resuscitation.' 'Patient care is at the heart of what we do, and we welcome the opportunity to implement treatments and techniques that may improve the outcome for patients suffering from traumatic injuries.' Data from the different international trials will be pooled for a meta-analysis, as each country faces unique challenges in pre-hospital transfusions. For New Zealand, the country's geography, relatively sparse population and the distances between emergency scenes and hospitals present a particular challenge, as Northern Rescue responds to some of the country's most remote and urgent rescue missions. Harper is optimistic the trial has the potential to positively impact patient outcomes. 'Care in motion can be challenging; whole blood potentially offers a simplicity to providing care by removing the added logistics of hanging and moving multiple bags of blood products and enabling faster treatment during a time when every second counts.' Northern Rescue takes its role as custodians of blood products seriously, with Harper acknowledging the fact every donation is a gift that has the potential to save a life. 'The longstanding partnership between Northern Rescue and NZBS has provided an opportunity to explore innovative new ways to approach emergency medical care. 'Thanks to the generosity of blood donors nationwide, in the decade since Northern Rescue became the first emergency service in Aotearoa to carry units of blood for pre-hospital transfusions, more than 300 units of blood have been used to provide the best possible care to around 200 patients.' Both Harper and Charlewood are primary investigators in the SWiFT Aotearoa trial, which will run for a minimum of 18 months and include data from up to 60 patients requiring pre-hospital blood transfusion. Analysis of the outcomes will begin shortly there-after. About Northern Rescue Northern Rescue Helicopter Limited is a joint venture between the Auckland Rescue Helicopter Trust (ARHT) and the Northland Emergency Services Trust (NEST) and is the contracted service provider to Health New Zealand | Te Whatu Ora and ACC for emergency air ambulance helicopter services in the northern region of Aotearoa New Zealand. It is the only aeromedical provider in New Zealand who provide a 24/7 doctor – critical care paramedic model of care and therefore the only emergency care provider in New Zealand able to transfuse blood products outside of hospital. Northern Rescue carries universal donor (O-negative) blood products on every flight, and responds to over 1,000 missions a year, providing medical care to critically unwell patients. If you would like to learn more about the lifesaving work of the rescue helicopters and find out how you can support, visit About New Zealand Blood Service New Zealand Blood Service (NZBS) in a not-for-profit Crown entity responsible for the collection, processing, testing and storage and distribution of all blood and blood products in New Zealand. We rely on voluntary and non-remunerated blood donations from individuals around the country in order to provide a constant supply of precious blood and blood products used by our health services to save thousands of lives. NZBS also provides cell and tissue products and related services to meet public health needs and maintains national oversight of organ donation and distribution.
Scoop
7 hours ago
- Scoop
Northern Rescue And New Zealand Blood Service Use Battlefield Insights To Take Partnership To New Heights
Northern Rescue Helicopter Limited, the operator of the Auckland Westpac Rescue Helicopter, and New Zealand Blood Service (NZBS) have launched a groundbreaking new trial, aiming to advance pre-hospital trauma care for some of Auckland, Northland and the Coromandel's most critically injured patients. The Study of Whole Blood in Frontline Trauma (SWiFT) Aotearoa trial builds on similar international trials in the United Kingdom and Canada. NZBS Transfusion Medicine Specialist Richard Charlewood says the New Zealand SWiFT trial, like those in the UK and Canada, will follow the learnings of military combat medicine, where the use of platelet rich whole blood transfusions has improved health outcomes for soldiers with severe trauma and blood loss. 'We often look to the military for lessons in emergency care. The unpredictable conditions they work in can push boundaries and lead to breakthroughs that have the ability to transform how civilian medical professionals respond in situations where every second counts.' The SWiFT Aotearoa trial will determine whether the inclusion of platelets in pre-hospital transfusion allows for earlier control of bleeding, potentially reducing the number of transfusions needed after arrival at the hospital and improving the probability of survival and recovery for patients. The randomised controlled trial will investigate the feasibility of making and delivering platelet-rich O-negative whole blood compared to the current O-negative whole blood carried by Northern Rescue for pre-hospital transfusion. Whole blood, like most blood components in New Zealand, has white cells removed, because they are not wanted and can cause reactions, but this process also removes the platelets. The platelet-rich whole blood is made using a new, more sophisticated filter that is able to remove the white cells while leaving most of the platelets. This trial aims to collect data on if platelet-rich whole blood might the be more effective for patients with life-threatening bleeding due to trauma. Platelets aid with blood clotting to stop bleeding and studies suggest that the earlier bleeding is brought under control, the better it is for the patient. Northern Rescue Deputy Medical Director Alana Harper describes the SWiFT Aotearoa trial as 'the next disruptive innovation in pre-hospital advanced resuscitation.' 'Patient care is at the heart of what we do, and we welcome the opportunity to implement treatments and techniques that may improve the outcome for patients suffering from traumatic injuries.' Data from the different international trials will be pooled for a meta-analysis, as each country faces unique challenges in pre-hospital transfusions. For New Zealand, the country's geography, relatively sparse population and the distances between emergency scenes and hospitals present a particular challenge, as Northern Rescue responds to some of the country's most remote and urgent rescue missions. Harper is optimistic the trial has the potential to positively impact patient outcomes. 'Care in motion can be challenging; whole blood potentially offers a simplicity to providing care by removing the added logistics of hanging and moving multiple bags of blood products and enabling faster treatment during a time when every second counts.' Northern Rescue takes its role as custodians of blood products seriously, with Harper acknowledging the fact every donation is a gift that has the potential to save a life. 'The longstanding partnership between Northern Rescue and NZBS has provided an opportunity to explore innovative new ways to approach emergency medical care. "Thanks to the generosity of blood donors nationwide, in the decade since Northern Rescue became the first emergency service in Aotearoa to carry units of blood for pre-hospital transfusions, more than 300 units of blood have been used to provide the best possible care to around 200 patients.' Both Harper and Charlewood are primary investigators in the SWiFT Aotearoa trial, which will run for a minimum of 18 months and include data from up to 60 patients requiring pre-hospital blood transfusion. Analysis of the outcomes will begin shortly there-after. About Northern Rescue Northern Rescue Helicopter Limited is a joint venture between the Auckland Rescue Helicopter Trust (ARHT) and the Northland Emergency Services Trust (NEST) and is the contracted service provider to Health New Zealand | Te Whatu Ora and ACC for emergency air ambulance helicopter services in the northern region of Aotearoa New Zealand. It is the only aeromedical provider in New Zealand who provide a 24/7 doctor - critical care paramedic model of care and therefore the only emergency care provider in New Zealand able to transfuse blood products outside of hospital. Northern Rescue carries universal donor (O-negative) blood products on every flight, and responds to over 1,000 missions a year, providing medical care to critically unwell patients. If you would like to learn more about the lifesaving work of the rescue helicopters and find out how you can support, visit About New Zealand Blood Service New Zealand Blood Service (NZBS) in a not-for-profit Crown entity responsible for the collection, processing, testing and storage and distribution of all blood and blood products in New Zealand. We rely on voluntary and non-remunerated blood donations from individuals around the country in order to provide a constant supply of precious blood and blood products used by our health services to save thousands of lives. NZBS also provides cell and tissue products and related services to meet public health needs and maintains national oversight of organ donation and distribution.
Scoop
15 hours ago
- Scoop
Faster, More Accurate Brain Tumour Diagnoses For Kiwis
Minister of Health More than 100 New Zealanders have already benefited from a groundbreaking diagnostic tool that is delivering faster, more accurate brain tumour diagnoses, Health Minister Simeon Brown says. DNA methylation profiling, the international gold standard for diagnosing brain tumours, has been rolled out at Auckland City Hospital over the past year. 'This technology is a game-changer for brain tumour diagnosis in New Zealand. It enables doctors to pinpoint the exact tumour type with greater precision and in less time, meaning patients can start the right treatment sooner,' Mr Brown says. 'Until now, diagnosis was typically made by microscopic examination. In some complex cases, samples were sent overseas for methylation profiling, but that could take up to six weeks. 'Having this cutting-edge capability in New Zealand means more Kiwi patients can access this advanced diagnostic technology locally. Turnaround times are faster, around four weeks, and quicker for urgent cases. 'It also means we can prioritise urgent cases, deliver answers sooner, and give patients and their families greater certainty.' In some recent cases done locally, methylation profiling has significantly altered the initial diagnosis. In others, it has identified rare or unexpected tumour types that may have been missed using traditional methods. The Auckland-based service is one of only three in Australasia, with samples from hospitals around the country also being sent to Auckland for analysis. Along with improving access and outcomes for patients, it is also significantly cheaper than sending samples offshore. 'Delivering faster access to cancer treatment is a key focus for the Government, which is why it is one of our five national health targets. Faster, more accurate diagnosis for brain tumours that may be cancerous is a vital part of that. 'By providing local access to the world's best diagnostic tools, we are improving outcomes for New Zealanders,' Mr Brown says.
